PureTech Health PLC (PRTC)

London
165.60
+7.00(+4.41%)
  • Volume:
    389,881
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    161.00 - 169.00

PRTC Overview

Prev. Close
158.6
Day's Range
161-169
Revenue
14.17M
Open
167
52 wk Range
145.8-410.66
EPS
-0.17
Volume
389,881
Market Cap
475.45M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
304,604
P/E Ratio
-
Beta
1.07
1-Year Change
-51.44%
Shares Outstanding
287,106,932
Next Earnings Date
-
What is your sentiment on PureTech Health PLC?
or
Market is currently closed. Voting is open during market hours.

PureTech Health PLC Company Profile

PureTech Health PLC Company Profile

Employees
250

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer’s disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer’s and Parkinson’s diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellNeutralBuySellStrong Sell
Technical IndicatorsStrong SellSellStrong BuySellStrong Sell
SummaryStrong SellNeutralStrong BuySellStrong Sell